AFFILIATIONS
1 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States
10 Stanford University, Stanford, California, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
12 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Donor-recipient sex combination is an established determinant of outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). Its impact in patients undergoing HLA-mismatched allo-HCT with post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis remains poorly defined. We evaluated the association between donor-recipient sex combination and transplant outcomes in this population.
Methods:
We conducted a retrospective analysis of patients undergoing first HLA-mismatched allo-HCT with PTCy-based GVHD prophylaxis using the Center for International Blood and Marrow Transplant Research (CIBMTR) P-6144 dataset. Patients were categorized by donor-recipient sex combination: male donor/male recipient (M/M), male donor/female recipient (M/F), female donor/male recipient (F/M), and female donor/female recipient (F/F). Overall survival (OS), GVHD-free/relapse-free survival (GRFS), and relapse-free survival (RFS) were estimated by Kaplan-Meier methods and compared with the log-rank test. Multivariable Cox proportional hazards models adjusted for clinically relevant covariates were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariable logistic regression evaluated GVHD, relapse, and non-relapse mortality (NRM). A two-sided p-value <0.05 was considered statistically significant.
Results:
A total of 7,055 patients were included: 2,658 M/M (37.7%), 1,623 M/F (23.0%), 1,449 F/M (20.5%), and 1,325 F/F (18.8%). Mean age was similar across groups (M/M 50.2, M/F 49.6, F/M 48.8, F/F 48.4 years). AML was the most common diagnosis (48.9–52.7%), followed by ALL (20.8–22.4%) and MDS/MPN (17.0–21.2%). Intermediate DRI predominated (57.8–64.2%). KPS 90–100 ranged from 54.4% (M/F) to 59.3% (M/M); HCT-CI ≥3 was present in approximately 43–48% of patients. Most received haploidentical donors (especially age ≥30) and peripheral blood grafts (75.2–77.6%). HLA 4/8 match was most frequent in M/M (67.7%) and least in F/F (58.1%). Recipient CMV-positive serostatus was higher in M/F (73.8%) and F/F (73.4%) than in M/M (66.9%) or F/M (66.0%). Crude rates of chronic GVHD requiring immunosuppressive therapy were lowest in M/M (22.5%) and highest in F/F (31.3%; overall p<0.001). Chronic GVHD overall (30.0% M/M to 38.9% F/F; p<0.001), NRM (highest in F/M at 24.2%; p<0.001), and death (highest in F/M at 49.7%; p<0.001) also differed significantly. Grade II–IV acute GVHD and relapse rates were comparable. In multivariable analysis, F/M transplantation was independently associated with inferior OS (HR 1.13, 95% CI 1.03–1.24; p=0.011), GRFS (HR 1.13, 95% CI 1.04–1.22; p=0.002), and RFS (HR 1.10, 95% CI 1.01–1.21; p=0.027) compared with M/M. M/F and F/F showed improved OS (HR 0.90, p=0.023 and HR 0.86, p=0.004) and RFS (HR 0.89, p=0.014 and HR 0.87, p=0.004). All non-M/M combinations had higher odds of chronic GVHD requiring immunosuppressive therapy (M/F OR 1.20, p=0.017; F/M OR 1.35, p<0.001; F/F OR 1.56, 95% CI 1.34–1.82, p<0.001). F/M was also associated with higher grade III–IV acute GVHD (OR 1.47, 95% CI 1.15–1.87; p=0.002) and NRM (OR 1.29, p=0.002). Relapse risk did not differ significantly by sex combination.
Conclusions:
Donor-recipient sex combination remains prognostically relevant in HLA-mismatched allo-HCT with PTCy. Compared with M/M, F/M transplantation is associated with inferior survival, higher severe acute GVHD, and increased NRM, while all non-M/M combinations carry elevated chronic GVHD risk. These findings support consideration of donor-recipient sex match during donor selection and risk stratification in the PTCy era.